Harold Selick
Chairman at MOLECULAR TEMPLATES, INC.
Net worth: 816 017 $ as of 31/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dinesh Patel | M | 67 |
Protagonist Pty Ltd.
 Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | 16 years |
| Samuel Saks | M | 69 |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 7 years |
| Eric Poma | M | 52 |
Molecular Templates OpCo, Inc.
 Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX. | 24 years |
| David Hoffmann | M | 79 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA
Molecular Templates OpCo, Inc.
Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX. | 7 years |
| Jason Kim | M | 49 |
Molecular Templates OpCo, Inc.
Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX. | 14 years |
| Carin M. Rollins | F | - |
Hinge Bio, Inc.
 Hinge Bio, Inc. BiotechnologyHealth Technology Hinge Bio, Inc. is a holding company, which engages in the development of specific and multi-specific antibodies. The company is headquartered in Burlingame, CA. | 19 years |
| Chaitan S. Khosla | M | 59 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | 7 years |
| Dominique Monnet | M | 65 | 7 years | |
| Julie Grant | F | 41 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | 3 years |
| Scott Morenstein | M | 48 |
Molecular Templates OpCo, Inc.
Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX. | 7 years |
| Gabriela Gruia | M | 67 | 2 years | |
| Kevin Lalande | M | 51 |
Molecular Templates OpCo, Inc.
Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX. | 15 years |
| Elizabeth O'Farrell | F | 59 | 6 years | |
| William Waddill | M | 67 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | 8 years |
| Volker Schellenberger | M | - |
Amunix, Inc.
 Amunix, Inc. Pharmaceuticals: MajorHealth Technology Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA. | - |
| Michael Broxson | M | - |
Molecular Templates OpCo, Inc.
Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX. | - |
| Kristen Quigley | F | 53 | 7 years | |
| Bryan Giraudo | M | 48 | 6 years | |
| Douglas Crawford | M | - |
Mission Bay Capital Management, Inc.
 Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | 15 years |
| Corazon Sanders | M | 67 | 5 years | |
| Tiffany Davis | F | - |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 21 years |
| Sarah O'Dowd | F | 74 | 4 years | |
| Christy Horgan | F | - | 7 years | |
| Hooman Shahlavi | M | - |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 17 years |
| Lewis Williams | M | 74 | 7 years | |
| Lars Ekman | M | 74 |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 17 years |
| Greg S. Yap | M | - |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | - |
| Craig Ostroff | M | - | - | |
| Asif Ali | M | 50 | 2 years | |
| Jack S. Wadsworth | M | 84 |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | - |
| Aaron Tward | M | - |
The University of California, San Francisco
| 2 years |
| Matthew M. Gosling | M | 53 | 4 years | |
| Carena Spivey | F | - | - | |
| William D. Unger | M | - |
Hinge Bio, Inc.
Hinge Bio, Inc. BiotechnologyHealth Technology Hinge Bio, Inc. is a holding company, which engages in the development of specific and multi-specific antibodies. The company is headquartered in Burlingame, CA. | - |
| Daniel J. Capon | M | - |
Hinge Bio, Inc.
Hinge Bio, Inc. BiotechnologyHealth Technology Hinge Bio, Inc. is a holding company, which engages in the development of specific and multi-specific antibodies. The company is headquartered in Burlingame, CA. | - |
| Suneel Gupta | M | 66 | 5 years | |
| Arturo Molina | M | 65 | 2 years | |
| Malcolm L. Gefter | M | - |
Hinge Bio, Inc.
Hinge Bio, Inc. BiotechnologyHealth Technology Hinge Bio, Inc. is a holding company, which engages in the development of specific and multi-specific antibodies. The company is headquartered in Burlingame, CA. | - |
| Brook Byers | M | 78 |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | - |
| Catherine Lynch Gilliss | M | 75 |
The University of California, San Francisco
| 7 years |
| Camille D. Samuels | F | 52 |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | - |
| Nicole Vitullo | F | 66 |
Hinge Bio, Inc.
Hinge Bio, Inc. BiotechnologyHealth Technology Hinge Bio, Inc. is a holding company, which engages in the development of specific and multi-specific antibodies. The company is headquartered in Burlingame, CA. | - |
| Ashok Bhandari | M | - | 7 years | |
| Walter Moos | M | 69 |
Amunix, Inc.
Amunix, Inc. Pharmaceuticals: MajorHealth Technology Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA. | 8 years |
| Peter D. Parker | M | 73 |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | - |
| Vivian Dang | F | - |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | 15 years |
| Patrick Heron | M | 53 |
Amunix, Inc.
Amunix, Inc. Pharmaceuticals: MajorHealth Technology Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA. | - |
| James Topper | M | 62 |
Amunix, Inc.
Amunix, Inc. Pharmaceuticals: MajorHealth Technology Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA. | 6 years |
| Robert Blazej | M | - |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | 7 years |
| Wende Hutton | F | 63 |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | - |
| Carter J. King | M | 52 | 6 years | |
| Daniel Swisher | M | 61 | 1 years | |
| Jon Root | M | 64 |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | - |
| Richard Heyman | M | 66 |
Amunix, Inc.
Amunix, Inc. Pharmaceuticals: MajorHealth Technology Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA. | - |
| Misha Petkevich | M | 75 |
Hinge Bio, Inc.
Hinge Bio, Inc. BiotechnologyHealth Technology Hinge Bio, Inc. is a holding company, which engages in the development of specific and multi-specific antibodies. The company is headquartered in Burlingame, CA. | - |
| Grace Kim | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| C. Payne | M | 61 |
Catalyst Bioscience, Inc. /Old/
 Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA. | 4 years |
| Adam Daniel Cutler | M | 50 | 4 years | |
| Augustine Lawlor | M | 67 |
Catalyst Bioscience, Inc. /Old/
Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA. | 17 years |
| Joel A. Fernandes | M | 54 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | - |
| Christine R. Larson | F | 71 | 3 years | |
| Edward A. Imbrogno | M | 60 | 3 years | |
| Jeff Bird | M | 63 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 16 years |
| Emily Lee Kelley | F | 66 |
Affymax Research Institute
 Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a private company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | 6 years |
| Michael S. Ostrach | M | 72 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 1 years |
| Stewart M. Kroll | M | 65 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 11 years |
| Donald Kalkofen | M | 60 | 3 years | |
| Thomas O'Neil | M | 59 | 3 years | |
| Mark L. Smythe | M | - | 16 years | |
| Andrea Hunt | F | 64 | 6 years | |
| Errol de Souza | M | 70 | 7 years | |
| Laura G. Hansen | M | - |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 4 years |
| Edward Williams | M | 68 | 4 years | |
| Lany Soesanto | F | - |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | - |
| Sarah Noonberg | M | 56 | 6 years | |
| Jeffrey Landau | M | 46 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 5 years |
| Nenad Sarapa | M | - | 1 years | |
| Conrad Jordaan | M | - | 2 years | |
| Jonathan Lanfear | M | 55 | 6 years | |
| Sean McLennan | M | 54 | 4 years | |
| Natasha Hernday | F | 52 | 3 years | |
| David Hirsch | M | 53 | 6 years | |
| Shlomo Yanai | M | 71 | 2 years | |
| John G. Curd | M | 78 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 4 years |
| Cathleen Phillips Davis | F | 70 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 2 years |
| Caroline J. Krumel | F | 60 | 2 years | |
| Bruce Cozadd | M | 60 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 12 years |
| Fredrick Frank | M | 92 | 3 years | |
| George Parker | M | 85 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 13 years |
| David Gryska | M | 68 | 6 years | |
| Nassim Usman | M | 64 |
Catalyst Bioscience, Inc. /Old/
Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA. | 9 years |
| David Parkinson | M | 73 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | - |
| Karen Wilson | F | 61 | 2 years | |
| George Tidmarsh | M | 64 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 4 years |
| John P. Richard | M | 66 | - | |
| Asish Xavier | M | - |
Catalyst Bioscience, Inc. /Old/
Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA. | 9 years |
| Paul Edick | M | 67 | 3 years | |
| Jody Lindell | F | 72 | 9 years | |
| Mark D. Matteucci | M | 70 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | - |
| Jami Taylor | M | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
| Australia | 4 | 4.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Harold Selick
- Personal Network
